Curis Inc (CRIS) - Financial and Strategic SWOT Analysis Review
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Curis Inc (CRIS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Curis Inc (Curis) is a biotechnology company that focuses on developing and commercializing novel drug candidates for treating human cancers with substantial unmet medical need in the US. It has three drug candidates in development, Fimepinostat (previously CUDC-907) for treating diffuse large B-cell lymphoma (DLBCL) and solid tumors; CA-170 for advanced solid tumors or lymphoma; CA-372 also for treating certain type of cancer, and CA-4948 for advanced non-Hodgkin lymphomas. The company in collaboration with F. Hoffmann-La Roche Ltd (or Roche) and Genentech (a member of the Roche group) has developed Erivedge (vismodegib), an orally-administered small molecule Hedgehog signaling pathway inhibitor and has been approved for the treatment of advanced basal cell carcinoma (BCC). Curis is headquartered in Lexington, Massachusetts, the US.
Curis Inc Key Recent Developments
May 12,2020: Curis reports first quarter 2020 financial results
Apr 21,2020: Curis receives loan under Paycheck Protection Program
Mar 19,2020: Curis reports fourth quarter and year-end 2019 financial results and provides business update
Nov 05,2019: Curis reports third quarter 2019 financial results
Sep 12,2019: Curis Announces Promotion of Bill Steinkrauss to Chief Financial Officer
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
The profile contains critical company information including:
- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Curis Inc (Curis) is a biotechnology company that focuses on developing and commercializing novel drug candidates for treating human cancers with substantial unmet medical need in the US. It has three drug candidates in development, Fimepinostat (previously CUDC-907) for treating diffuse large B-cell lymphoma (DLBCL) and solid tumors; CA-170 for advanced solid tumors or lymphoma; CA-372 also for treating certain type of cancer, and CA-4948 for advanced non-Hodgkin lymphomas. The company in collaboration with F. Hoffmann-La Roche Ltd (or Roche) and Genentech (a member of the Roche group) has developed Erivedge (vismodegib), an orally-administered small molecule Hedgehog signaling pathway inhibitor and has been approved for the treatment of advanced basal cell carcinoma (BCC). Curis is headquartered in Lexington, Massachusetts, the US.
Curis Inc Key Recent Developments
May 12,2020: Curis reports first quarter 2020 financial results
Apr 21,2020: Curis receives loan under Paycheck Protection Program
Mar 19,2020: Curis reports fourth quarter and year-end 2019 financial results and provides business update
Nov 05,2019: Curis reports third quarter 2019 financial results
Sep 12,2019: Curis Announces Promotion of Bill Steinkrauss to Chief Financial Officer
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
TABLE OF CONTENTS
Section 1 - About the Company
Curis Inc - Key Facts
Curis Inc - Key Employees
Curis Inc - Key Employee Biographies
Curis Inc - Major Products and Services
Curis Inc - History
Curis Inc - Company Statement
Curis Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 Company Analysis
Company Overview
Curis Inc - Business Description
Curis Inc - Corporate Strategy
Curis Inc - SWOT Analysis
SWOT Analysis - Overview
Curis Inc - Strengths
Curis Inc - Weaknesses
Curis Inc - Opportunities
Curis Inc - Threats
Curis Inc - Key Competitors
Section 3 Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 Companys Lifesciences Financial Deals and Alliances
Curis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Curis Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Curis Inc, Recent Deals Summary
Section 5 Companys Recent Developments
May 12, 2020: Curis reports first quarter 2020 financial results
Apr 21, 2020: Curis receives loan under Paycheck Protection Program
Mar 19, 2020: Curis reports fourth quarter and year-end 2019 financial results and provides business update
Nov 05, 2019: Curis reports third quarter 2019 financial results
Sep 12, 2019: Curis Announces Promotion of Bill Steinkrauss to Chief Financial Officer
Aug 13, 2019: Curis hires industry veterans to lead clinical development and regulatory affairs
Aug 06, 2019: Curis reports second quarter 2019 financial results
May 14, 2019: Curis Reports first quarter 2019 financial results
Mar 26, 2019: Curis announces fourth quarter and year-end 2018 financial results
Section 6 Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List Of Tables
Curis Inc, Key Facts
Curis Inc, Key Employees
Curis Inc, Key Employee Biographies
Curis Inc, Major Products and Services
Curis Inc, History
Curis Inc, Subsidiaries
Curis Inc, Key Competitors
Curis Inc, Ratios based on current share price
Curis Inc, Annual Ratios
Curis Inc, Annual Ratios (Cont...1)
Curis Inc, Interim Ratios
Curis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Curis Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Curis Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List Of Figures
Curis Inc, Performance Chart (2015 - 2019)
Curis Inc, Ratio Charts
Curis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Curis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020
RELATED REPORTS
SAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
![]() |
The report was self-explanatory and did not require a great deal of analysis. This helped a timely-decision making and served our purpose well. Thanks |